Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bernstein Remains a Buy on BeOne Medicines AG (ONC)

Bernstein Remains a Buy on BeOne Medicines AG (ONC)

FinvizFinviz2026/02/13 10:21
By:Finviz

BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from $385 to $394.

​The bullish sentiment follows the first-in-world approval of BeOne’s Sonrotoclax in China to treat adults with two hard-to-treat blood cancers. These include relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory chronic lymphocytic leukemia (CLL). The approval in China was based on the MCL study and CLL/SLL study presented at the 2025 ASH conference.

Bernstein Remains a Buy on BeOne Medicines AG (ONC) image 0

​The MCL study demonstrated 52.4% overall response rate per independent review, and the CLL/SLL study showed 77% ORR per independent review. Management noted that the approval in China is part of a global rollout strategy.

Rebecca Liang from Bernstein believes BeOne Medicines AG (NASDAQ:ONC) to be undervalued considering its pipeline. She noted that “the pipeline is not recognized by the market,” and highlighted Sonrotoclax as “potential best-in-class status.”

​BeOne Medicines AG (NASDAQ:ONC), based in Switzerland,  is a global oncology company focused on discovering and developing innovative cancer treatments for hematology and solid tumors worldwide.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue

Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.

智通财经•2026/11/13 03:52

Microsoft (MSFT.US) offers voluntary buyout packages to about 60,000 employees: Structural divergence in U.S. employment under AI transformation

In 2026, the U.S. labor market is characterized by both low layoffs and weak hiring. Companies like Microsoft and American Express are leveraging AI to optimize their workforce, while data centers are driving growth in the construction sector. However, entry-level white-collar jobs face increasing pressure, with real wages experiencing negative growth and structural transformation risks becoming more prominent.

智通财经•2026/11/13 03:51
Microsoft (MSFT.US) offers voluntary buyout packages to about 60,000 employees: Structural divergence in U.S. employment under AI transformation

"Inflation is really too high"! Federal Reserve "third-in-command": The Fed must continue to take action and promptly bring the price level back to 2%

John Williams, President of the New York Federal Reserve and the “number three” official at the Federal Reserve with a permanent voting right, stated that U.S. inflation remains high and policymakers must take further action to curb price pressures.

智通财经•2026/11/13 03:27
"Inflation is really too high"! Federal Reserve "third-in-command": The Fed must continue to take action and promptly bring the price level back to 2%